This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

TD-1792

Theravance Biopharma, Inc.

Drug Names(s): TD-1792

Description: TD-1792 is an investigational heterodimer antibiotic that combines the aspects of both glycopeptide and cephalosporin antibiotic mechanisms into a single molecule.

Deal Structure: Theravance and Astellas
In July 2006, Astellas, in addition to the license rights to telavancin in Japan, also received an option to further develop and commercialize TD-1792 in Japan.

In September 2007, Theravance announced that Astellas Pharma has elected not to exercise its option to license TD-1792 under the terms of the companies' 2005 License, Development, and Commercialization Agreement. Theravance retains all rights to develop and commercialize this asset on its own or in partnership with other companies.

Theravance and R-Pharm
In October 2012, Theravance announced that the Company entered into two separate development and commercialization agreements with R-Pharm. The first was for TD-1792, Theravance's investigational glycopeptide-cephalosporin heterodimer antibiotic for the treatment of resistant Gram-positive infections. The second was for telavancin, Theravance's lipoglycopeptide antibiotic approved in the US. In both of the agreements,...See full deal structure in Biomedtracker

Partners: R-Pharm Group


TD-1792 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug